Qiagen stole trade secrets, infringed a patent, and engaged in deceptive trade practices to make products that compete with those of ArcherDX, the closely held genetic-sequencing company said in a lawsuit.

Archer is seeking, among other remedies, damages and all Qiagen profits derived from its unlawful conduct and court orders blocking sales of QIAseq Kits and the use of Archer trade secrets, according to a complaint filed July 11 in federal court in Wilmington, Del.

Archer’s technology enables determination of nucleotide sequences found in many cancers. The patent, related to methods of determining sequences of short nucleotide chains, was issued...